Other News
Combining traditional medicine with modern medicine in medical examination and treatment
Combining traditional medicine with modern medicine in medical examination and treatment
The method of combining traditional medicine with modern medicine is the combination of medical examination and treatment methods of traditional medicine with medical examination and treatment methods of modern medicine on the same patient in order to improve the quality of medical examination and treatment to ensure safety, effective.
Ligusticum striatum and Angelica dahurica: A duo of precious medicinal herbs for panacea
Ligusticum striatum and Angelica dahurica: A duo of precious medicinal herbs for panacea
Ligusticum striatum and  Angelica dahurica: are two precious medicines that are used a lot in the treatment of diseases. In traditional medicine, these two medicines are often combined with each other in colds, leprosy, headaches ...
A Guide to Administering Influenza Vaccines in Special Populations: Focus on Patients Who Are Immunocompromised
A Guide to Administering Influenza Vaccines in Special Populations: Focus on Patients Who Are Immunocompromised

Seasonal influenza virus is associated with considerable morbidity and mortality each year in the United States. Most people recover from influenza illness without requiring medical attention; however, among those who are immunocompromised, influenza can cause severe illness, complications, and death. Patients who are immunocompromised experience greater morbidity and mortality from vaccine-preventable illnesses, including influenza, due to an insufficient immune response. Because of these risks, influenza vaccination is a critical strategy to prevent infection in this patient population.

FDA Issues EUA for Combined Test for COVID-19, RSV, Influenza

FDA has granted an Emergency Use Authorization (EUA) for the combined test of the BD MAX Molecular Diagnostic System by Becton, Dickinson, and Company for SARS-CoV-2, influenza A+B, and respiratory syncytial virus. respiratory tract (RSV).

The test involves a single nasal swab or nasopharyngeal swab to determine if a patient has COVID-19, influenza, RSV, or a combination of the three viruses. This system is an RT-PCR test that detects and distinguishes nucleic acids of SARS-CoV-2, influenza A, influenza B and RSV in just 2 hours to get initial test results.

Nikos Pavlidis, vice president of Molecular Diagnostics at BD, said: “Although fears of a 'triple pandemic' this respiratory season have largely subsided, the precise distinction of influenza has not yet been achieved. and RSV with COVID-19 and providing appropriate treatment remains a challenge for our customers.” "This diagnostic test provides the ability to identify multiple pathogens using a single sample and can rapidly identify the causative virus or virus and allows clinicians to appropriate treatment early in the course of the infection."

The new molecular diagnostic test could eliminate the need for multiple tests or visits to the doctor, and could allow providers to start the correct treatment process faster. Co-testing can also help improve testing capacity during peak respiratory transmission seasons and speed up the time to diagnosis.

The BD MAX system is already in use in thousands of hospitals and laboratories around the world and can analyze hundreds of samples in a 24-hour period, according to BD. According to the EUA, this test has not been approved or approved by the FDA but is authorized for emergency use by authorized laboratories.

The test is only allowed to detect and differentiate nucleic acids of SARS-CoV-2, influenza A, influenza B and RSV and is not used to detect any other viruses or pathogens.

This test follows the launch of Roche's new COVID-19 polymerase chain reaction (PCR) test that specifically targets the XBB.1.5 Omicron subvariant and runs on the LightCycler 480 II real-time PCR platform and cobas z480. 2

The test, called VirSNiP SARS-CoV-2 Spike F486P, is for research purposes only and specifically targets the unique mutation F486P found in the XBB.1.5 Omicron sub-variant. Typical clinical specimens are throat and nasopharyngeal swabs, sputum, saliva, or gargle solution.

The ability to test for and differentiate the new COVID-19 sub-variant will help experts make predictions about the spread and respond with tailored treatment strategies. In particular, the XBB.1.5 variant is popular in the US and is rapidly spreading to other countries

These new testing options can help service providers quickly quell outbreaks caused by the combined effects of all three seasonal illnesses.